Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 5, 2013, Pages

  Rudin, Charles M ^a   Hong, Kelvin ^a   Streit, Michael ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DABRAFENIB; ERLOTINIB; GEMCITABINE; K RAS PROTEIN; NAVELBINE; PACLITAXEL; PEMETREXED;

ADULT; BRAF ONCOGENE; CANCER GROWTH; CANCER RADIOTHERAPY; CASE REPORT; CLONOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DYSPNEA; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; NOTE; ONCOGENE; OUTCOME ASSESSMENT; PATIENT REFERRAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; REPEAT PROCEDURE; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 84876419277     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31828bb1b3     Document Type: Article

References (5)

1. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046-2051.
2. Ji H, Wang Z, Perera SA, et al. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007;67:4933-4939.
3. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer January 2, 2013 [epub ahead of print].
4. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150:1107-1120.
5. Lito P, Pratilas CA, Joseph E W, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 2012;22:668-682.